Speaking to Clinical Trials Arena, Olema CEO Sean Bohen said that the first patient in Phase III will be dosed before the end of 2023.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,